NeoCOAST-2 Lung Cancer Trial: ctDNA Clearance Linked to Longer Event-Free Survival

3.0 · 6d ago · WORLD

The Facts

  • NeoCOAST-2 (NCT05061550) is a phase 2 randomised platform trial testing perioperative treatments in patients with stage IIA–IIIB resectable non-small cell lung cancer. Nature only
  • All arms combined chemotherapy plus durvalumab with oleclumab (Arm 1, n=76), monalizumab (Arm 2, n=72) or datopotamab deruxtecan (Dato-DXd; Arm 4, n=54). Nature only
  • At primary analysis, pathological complete response rates were 20.3%, 25.7% and 35.2% in Arms 1, 2 and 4, respectively. Nature only
  • 24-month event-free survival rates were 70.5% (Arm 1), 75.7% (Arm 2) and 77.9% (Arm 4). Nature only
  • ctDNA clearance at neoadjuvant Cycle 3 Day 1 was 50.9%, 54.5% and 72.5% in Arms 1, 2 and 4, respectively, using a tumour-agnostic assay. Nature only
Dive deeper · 3 more factsShow less
  • ctDNA clearance correlated with longer EFS versus non-clearance (pooled HR 0.22; 95% CI 0.11–0.45). Nature only
  • Patients with both ctDNA clearance and pCR had better EFS than those with neither (HR 0.10; 95% CI 0.02–0.42). Nature only
  • The authors, including AstraZeneca researchers, conclude that the numerically highest pCR and EFS rates with the Dato-DXd combination warrant further evaluation. Nature only

Context

A paper in Nature reports the first prespecified secondary endpoint results from NeoCOAST-2, a phase 2 trial in resectable non-small cell lung cancer. Authors include AstraZeneca employees.

The authors say combined assessment of ctDNA clearance and pathological complete response may improve risk stratification. Arm comparisons are numerical in a phase 2 setting.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 2.

4 Science & Tech Analyst This is a peer-reviewed phase 2 trial secondary-endpoint publication in Nature with small sample sizes and non-randomised-level arm comparisons, offering incremental insight into ctDNA as a biomarker in lung cancer rather than a practice-changing breakthrough.
3 Business Analyst This is a single-source phase 2 academic trial publication with small arms and non-randomized numerical comparisons, reporting biomarker associations rather than an approved therapy or market-moving corporate or regulatory action, so its impact is limited to the oncology research community.
3 Global Affairs Analyst This is a single-source phase 2 trial secondary-endpoint publication in Nature showing ctDNA clearance correlating with survival, a scientifically interesting but niche oncology finding with no immediate broad impact or regulatory action.
3 News Editor This is a single phase 2 trial's secondary endpoint publication in a niche clinical oncology context, with small sample sizes, numerical-only arm comparisons, and one independent source, so it has limited immediate impact on patients or the public.
3 Policy Expert This is a single-source phase 2 trial publication reporting exploratory biomarker correlations (ctDNA clearance and EFS) with no regulatory approval, policy change, or immediate clinical practice change, so its impact is limited to a niche research community.
3 Critical Reader This is a single phase 2 trial's secondary biomarker analysis published in a journal, with small arms, non-randomised comparisons, and no change in practice or patient outcomes, so it is niche, limited-impact research news.
2 Informed Citizen This is a single-source phase 2 trial secondary-endpoint publication in a niche research area with no immediate change for patients or practice, so its impact over the coming week is minimal.

Source

← All stories